Semaglutide Market Hits Speed Bump With ₹100 Crore Excess Stock
The explosive growth of India's obesity therapy market has faced an unexpected setback as sluggish sales in May led to a massive inventory buildup. Following a massive surge driven by generic entries, the semaglutide segment is now grappling with an estimated ₹100 crore worth of excess stock sitting in the trade channel.
The Post-Patent Surge and Subsequent Slowdown
The obesity therapy market, currently valued at approximately ₹2,000 crore, experienced a massive windfall in April. This surge was triggered by the patent expiry of semaglutide on March 20, which opened the floodgates for cheaper generic versions from major Indian pharmaceutical players including Sun Pharma, Dr. Reddy's, and Torrent Pharmaceuticals. In April, the market saw a staggering 50% month-on-month (m-o-m) growth in value and an 88% jump in volume.
However, this momentum failed to sustain into May. Data from market research firm Pharmarack indicates that value growth decelerated to just 6% m-o-m, while unit growth slowed to 12%. This sudden cooling of demand has left wholesalers and stockists in a difficult position.
Inventory Overhang Strains the Supply Chain
According to Rajiv Singhal, General Secretary of the All India Organisation of Chemists and Druggists (AIOCD), there is a significant inventory overhang across the country. While the standard inventory cycle for pharmaceutical products typically ranges between 30 to 45 days, stockists and wholesalers are currently holding 50 to 60 days' worth of GLP-1 (semaglutide) stock.
The scale of the surplus is substantial, with industry estimates suggesting the excess stock in the trade channel is worth nearly ₹100 crore. As a result, channel partners have implemented a freeze on fresh procurement from pharmaceutical manufacturers, waiting for existing inventories to liquidate before placing new orders.
Regulatory Impact and Competitive Landscape
Industry experts suggest that the moderation in sales may not be purely a market correction but could be linked to recent regulatory shifts. In April, government advisories and prescribing restrictions were introduced, stipulating that GLP-1 therapies must only be prescribed by qualified specialists. These tighter guidelines may have contributed to the sudden dip in consumer access and prescription volume.
Despite the semaglutide slowdown, the broader GLP-1 receptor agonist market shows resilience in specific segments. Eli Lilly’s Mounjaro (tirzepatide) remained the top-selling therapy in the pharma market during May, with sales climbing 12% to reach ₹136 crore. This performance occurred even as the wider ₹2.5 lakh crore organized pharma retail sector grew by 11%, driven largely by chronic disease therapies.
Key Takeaways
- Massive Inventory Surplus: The semaglutide trade channel is facing an estimated ₹100 crore excess stock, with wholesalers holding up to 60 days of inventory.
- Growth Deceleration: After a 50% value surge in April due to generic launches, May saw growth plummet to just 6% m-o-m.
- Regulatory Headwinds: Stricter prescribing guidelines requiring specialist intervention are believed to be a key factor in the cooling demand.